Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Find out about why a family of chromatin-interacting proteins – the BET proteins – are an attractive target for drug development, in a new review article by Panagis Filippakopoulos and Chen-Yi Wang.